Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Kurt · SciRah

Researcher profile · Semantic Scholar

M. Kurt

Share profile

M. Kurt — researcher profile on SciRah

h-index: 6
Works: 85
Citations: 146

Most-cited papers

Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial
S. Branchoux, C. L. Sofeu, A. Gaudin, M. Kurt +4 more
2021ESMO Open28 citations Open access
Semantic Scholar
Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis.
J. Ajani, L. Leung, Prianka Singh, M. Kurt +3 more
2022European Journal of Cancer26 citations Open access
Semantic Scholar
What Did Time Tell Us? A Comparison and Retrospective Validation of Different Survival Extrapolation Methods for Immuno-Oncologic Therapy in Advanced or Metastatic Renal Cell Carcinoma
S. Klijn, E. Fenwick, S. Kroep, K. Johannesen +4 more
2021PharmacoEconomics (Auckland)19 citations
Semantic Scholar
Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma
Victoria Federico Paly, M. Kurt, Li-Rong Zhang, M. Butler +7 more
2022MDM Policy & Practice16 citations Open access
Semantic Scholar
Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067
T. Baker, H. Johnson, S. Kotapati, A. Moshyk +3 more
2022PharmacoEconomics - Open12 citations Open access
Semantic Scholar
1746P Disease-free survival (DFS) and distant metastasis-free survival (DMFS) as surrogates for overall survival (OS) in adjuvant treatment of muscle-invasive bladder cancer (MIBC)
C. Sternberg, P. Squifflet, S. Burdett, D. Fisher +14 more
2022Annals of Oncology6 citations Open access
Semantic Scholar
PCN451 MODELING THE SURVIVAL BENEFIT OF IMMUNO-ONCOLOGIC THERAPY: A REVIEW OF METHODS USED IN NICE SINGLE TECHNOLOGY APPRAISALS
S. Kroep, C. Kiff, C. Kraan, M. Bianco +7 more
2019Value in Health4 citations Open access
Semantic Scholar
Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma
S. Petersohn, B. McGregor, S. Klijn, J. May +8 more
2023Journal of Comparative Effectiveness Research3 citations Open access
Semantic Scholar
1105P Estimating long-term survivorship in patients with advanced melanoma treated with immune-checkpoint inhibitors: Analyses from the phase III CheckMate 067 trial
P. Mohr, J. Larkin, V. Paly, A. Azocar +8 more
20203 citations Open access
Semantic Scholar
1459P Analysis of long-term efficacy outcomes from the CheckMate 025 (CM 025) trial comparing nivolumab (NIVO) vs everolimus (EVE) based on ≥ 7 years (yrs) of follow-up in pre-treated patients (pts) with advanced renal cell carcinoma (aRCC)
B. Escudier, R. Motzer, M. Dyer, J. May +8 more
2022Annals of Oncology2 citations Open access
Semantic Scholar
1218P Long-term survivorship rates among chemotherapy refractory or intolerant advanced esophageal squamous cell carcinoma (aESCC) patients treated with nivolumab (NIVO)
J. Ajani, D. Sharpe, T. De, I. Kim +2 more
2022Annals of Oncology2 citations Open access
Semantic Scholar
MSR38 Can Logistic Regression (LOR) Better Predict the Significance of the Overall Survival (OS) from Surrogate Endpoints (SES) for Randomized Controlled Trials (RCTS) in Oncology? Insights From a Cross-Tumor Case Study
O. Alagoz, S. Srinivasan, I. Kim, M. Kurt
2022Value in Health2 citations Open access
Semantic Scholar
Mixture-cure modeling for resected stage III/IV melanoma in the phase III CheckMate 238 trial
J. Weber, M. Kurt, M. Edmondson-Jones, A. Amadi +4 more
2019Annals of Oncology2 citations Open access
Semantic Scholar
CO153 Predicting Overall Survival (OS) Benefit in Previously Untreated Metastatic Melanoma From Improvements in Response Outcomes: A Correlation Meta-Analysis of Randomized Controlled Trials (RCTs)
L. Leung, P. Serafini, S. Srinivasan, F. Ejzykowicz +3 more
2024Value in Health1 citations
Semantic Scholar
CO29 Post Distant Recurrence (DR) Survival of Muscle-Invasive Urothelial Carcinoma (MIUC) Patients with Prior Radical Cystectomy (RC): Analysis of a Flatiron Real-World Cohort Matched to CheckMate-274
M. Lambton, K. Nickel, M. Patel, M. Kurt +3 more
2023Value in Health1 citations
Semantic Scholar
P49 Evaluation of Surrogate Endpoints (SES) for Previously Untreated Unresectable or Metastatic Melanoma (MMEL): Analyses from a Longitudinal Electronic Health Record Database in the United States (US)
L. Leung, P. Mohr, P. Serafini, S. Kanters +4 more
2023Value in Health1 citations Open access
Semantic Scholar
P27 The Impact of Incorporating Survival Heterogeneity into Modeling of Survival Outcomes for Patients with Muscle-Invasive Bladder Cancer after Radical Resection: Analyses from a Retrospective Real-World Study in France
K. Chepynoga, T. De, M. Kurt, F. Colrat +3 more
2023Value in Health1 citations
Semantic Scholar
CO205 Evaluating Disease-Free Survival (DFS) As a Surrogate Endpoint (SE) for Overall Survival (OS) in Muscle-Invasive Urothelial Carcinoma (MIUC): An Analysis of Surveillance, Epidemiology, and End Results (SEER)-Medicare Data
L. Leung, S. Kanters, M. M. Pourrahmat, H. Friedman +6 more
2023Value in Health1 citations
Semantic Scholar
CO54 Recurrence-Free Survival (RFS) as a Surrogate Endpoint (SE) for Overall Survival (OS) in Resected Stage II/III Melanoma: A Correlation Meta-Analysis of Randomized Controlled Trials (RCTs)
L. Leung, J. Kirkwood, S. Srinivasan, M. Dyer +6 more
2023Value in Health1 citations Open access
Semantic Scholar
POSA24 Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in Previously Untreated Advanced Melanoma: A Correlation Meta-Analysis of Randomized Controlled Trials (RCTS)
L. Leung, E. Chou, M. Kurt, A. Moshyk +3 more
2022Value in Health1 citations Open access
Semantic Scholar
POSC308 Network Meta-Analysis Under Survival Heterogeneity with Long-Term Survival: A Case Study from Adjuvant Treatment of Resected Stage III/IV Melanoma
K. Toor, S. Goring, K. Chan, M. Kurt +4 more
2022Value in Health1 citations Open access
Semantic Scholar
816P Investigating surrogate endpoints (SE) for overall survival (OS) in first-line (1L) advanced melanoma: A pooled-analysis of immune checkpoint inhibitor (ICI) trials
J. Larkin, P. Squifflet, E. Saad, P. Mohr +5 more
2022Annals of Oncology1 citations Open access
Semantic Scholar
Network meta-analysis (NMA) of first-line advanced renal cell carcinoma (1L aRCC) treatments: Development of a decision algorithm for fractional polynomial (FP) model selection.
B. McGregor, S. Petersohn, S. Klijn, J. May +5 more
2022Journal of Clinical Oncology1 citations
Semantic Scholar
MSR104 Assessing the Impact of Integrating Extrapolated Long-Term Outcomes Into Elicitation of Unreported Subgroup-Specific Survival in Randomized Controlled Trials (RCTS): Insights From Advanced Stage Gastrointestinal Cancers
O. Alagoz, S. Srinivasan, H. Xiao, P. Singh +4 more
2022Value in Health1 citations Open access
Semantic Scholar
CO55 Radiographic Progression-Free Survival (RPFS) as a Surrogate Endpoint for Overall Survival (OS) in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (MCRPC): A Correlation Meta-Analysis
L. Leung, M. Patel, S. Teitsson, K. Hofer +2 more
2022Value in Health1 citations Open access
Semantic Scholar
POSB8 Efficacy and Safety Results from Randomized Controlled Trials (RCTS) Evaluating Adjuvant Treatment after Radical Resection (RR) of Muscle Invasive Urothelial Carcinoma (MIUC): A Systematic Literature Review (SLR)
A. Trip, A. Shree, D. Rekowska, S. Teitsson +4 more
2022Value in Health1 citations Open access
Semantic Scholar
1456P Long-term survivorship rates for first-line intermediate or poor (I/P) risk advanced renal cell carcinoma (aRCC) patients achieving objective response (OR) with nivolumab plus ipilimumab (N+I)
S. George, M. Hunger, O. Hughes, J. May +3 more
2022Annals of Oncology1 citations Open access
Semantic Scholar
CO153 Survival Analyses and Indirect Treatment Comparisons (ITCS) in First-Line Metastatic Urothelial Carcinoma (1L MUC)
M. Jevdjevic, K. Nickel, S. Teitsson, M. Kurt +3 more
2022Value in Health1 citations Open access
Semantic Scholar
POSB302 Assessing the Viability of a Surrogacy Relationship between Disease-Free Survival (DFS) and Overall Survival (OS) for the Patients in Clinical Trials for Adjuvant Treatment of Muscle-Invasive Urothelial Carcinoma (MIUC) Following Radical Cystectomy.
A. Barkema, C. Simons, M. Kurt, E. Broughton +3 more
2022Value in Health1 citations Open access
Semantic Scholar
P47 A Bayesian Hierarchical Mixture Cure Modelling (MCM) Framework for the Joint Utilization of Progression Free Survival (PFS) and Overall Survival (OS) in Estimating Long-Term Survivorship Rates in Previously Untreated Metastatic Melanoma: A Case Study from CheckMate-067 Trial
N. Green, V. Paly, JH Youn, M. Kurt +2 more
2022Value in Health1 citations Open access
Semantic Scholar
PCN42 Real-World Effectiveness in Previously Untreated, Advanced/Metastatic Renal Cell Carcinoma – a Systematic Literature Review Update
A. Trip, J. May, B. Malcolm, F. Ejzykowicz +5 more
20201 citations Open access
Semantic Scholar
ON4 Heterogeneity in Survival with Immuno-Oncologic Therapy and Its Implications for Survival Extrapolations: A Case Study in Untreated Metastatic Melanoma
V. Paly, M. Kurt, L. Zhang, A. Amadi +4 more
20201 citations Open access
Semantic Scholar
PDG5 Updated Lifetime Survival Estimates for Nivolumab+ipilimumab in Previously Untreated Advanced/Metastatic Intermediate- or Poor-Risk Renal Cell Carcinoma (1L aRCC)
V. Qendri, J. May, B. Malcolm, F. Ejzykowicz +3 more
20201 citations Open access
Semantic Scholar
PCN21 Efficacy and Safety in Previously Untreated, Advanced/Metastatic Renal Cell Carcinoma – a Systematic Literature Review Update
C. Kraan, L. Nientker, J. May, B. Malcolm +6 more
20201 citations Open access
Semantic Scholar
Evaluating surrogates for overall survival in the adjuvant treatment of bladder cancer with chemotherapy
C. Sternberg, P. Squifflet, E. Saad, S. Burdett +14 more
2025Urologic oncology0 citations Open access
Semantic Scholar
CO115 Long-Term Post-Recurrence Survival (PRS) Outcomes for Stage IIB/C Melanoma Patients in Real-World (RW) Settings: Analyses from a Longitudinal Electronic Health Record Database in the United States
M. Kurt, Y. Zhang, S. Srinivasan, M. Dyer +2 more
2024Value in Health0 citations
Semantic Scholar
P30 Semi-Markov Model (sMM) Versus Trial-Level Surrogacy to Predict Overall Survival (OS) for Adjuvant Treatment of Muscle-Invasive Urothelial Carcinoma (MIUC) with Chemotherapy
A. Berardi, M. Kurt, S. Cope, C. V. van Beurden-Tan +2 more
2024Value in Health0 citations
Semantic Scholar
MSR97 Indirect Estimation of Post-Distant Recurrence Survival (PDRS) for Resected Stage II/III Melanoma: A Network-Meta Analysis (NMA) Approach
M. Kurt, K. Toor, Y. Zhang, C. Smare +5 more
2024Value in Health0 citations Open access
Semantic Scholar
MSR12 Analysis of Long-Term Survivorship (LTS) Rates for Stage 2B/2C Melanoma Using Published Real-World Data (RWD) and Data From Randomized Controlled Trials (RCTS)
O. Alagoz, A. Winge-Main, S. Srinivasan, M. Dyer +5 more
2023Value in Health0 citations
Semantic Scholar
MSR54 Exploring Hidden Survival Heterogeneity Among First-Line (1L) Intermediate/Poor (I/P)-Risk Advanced Renal Cell Carcinoma (ARCC) Patients Treated with Nivolumab Plus Ipilimumab (NIVO+IPI) Via Parametric Mixture Models (PMM)
M. Hunger, S. George, M. Dyer, F. Ejzykowicz +2 more
2023Value in Health0 citations
Semantic Scholar
An indirect assessment of individual-level association between disease-free survival (DFS) and overall survival (OS) for resectable esophageal or gastroesophageal junction cancer (EC/GEJC): A pooled analysis of randomized controlled trials (RCTs) by an illness-death model.
O. Alagoz, J. Ajani, Swetha Srinivasan, I. Kim +2 more
2023Journal of Clinical Oncology0 citations
Semantic Scholar
Disease-free survival (DFS) as a surrogate endpoint (SE) for overall survival (OS) in early-stage resected esophageal/gastroesophageal junction cancer (EC/GEJC): An analysis of SEER-Medicare data.
J. Ajani, L. Leung, S. Kanters, Prianka Singh +6 more
2023Journal of Clinical Oncology0 citations Open access
Semantic Scholar
EE41 Cost-Utility of Nivolumab Versus Observation for the Adjuvant Treatment of Urothelial Carcinoma (UC) for Patients Who Are at High-Risk of Recurrence: A Canada Public Payer Perspective
J. Graham, W. Kassouf, D. Tomaras, M. Kurt +2 more
2023Value in Health0 citations
Semantic Scholar
Long-term survivorship rates among patients with previously treated advanced renal cell carcinoma receiving nivolumab: Analyses based on ≥ 7 years of follow-up from CheckMate 025 trial.
S. George, J. Larkin, Kateryna Chepynoga, D. Sharpe +5 more
2023Journal of Clinical Oncology0 citations Open access
Semantic Scholar
EE693 Assessing the Impact of Additional Follow-up From the CheckMate-274 Trial on the Cost-Effectiveness (CE) Profile of Nivolumab Versus Surveillance in High-Risk, Muscle-Invasive Urothelial Carcinoma (MIUC)
T. Chandler, I. Orsini, C. V. van Beurden-Tan, M. Kurt +2 more
2023Value in Health0 citations
Semantic Scholar
CO141 Assessing the Impact of Additional Follow-up Data on Disease-Free Survival (DFS) Projections of Nivolumab and Surveillance in High-Risk, Muscle-Invasive Urothelial Carcinoma (MIUC) Patients Within the CheckMate-274 Trial
T. Chandler, I. Orsini, C. V. van Beurden-Tan, M. Kurt +2 more
2023Value in Health0 citations
Semantic Scholar
MSR12 Eliciting Unreported Subgroup-Specific Survival in Randomized Controlled Trials (RCTS): A Non-Parametric Linear Optimization Approach
O. Alagoz, S. Srinivasan, H. Xiao, P. Singh +4 more
2022Value in Health0 citations Open access
Semantic Scholar
POSC389 Characterisation of Existing Treatment Patterns in Muscle-Invasive Urothelial Carcinoma (MIUC) Across North America, Europe, and East Asia
E. Broughton, S. Teitsson, S. Huo, M. Kurt +4 more
2022Value in Health0 citations Open access
Semantic Scholar
EE370 Assessing the Impact of Crossover Adjustment on the Cost-Effectiveness (CE) of Nivolumab Versus Everolimus in Pre-Treated Advanced Renal Cell Carcinoma (ARCC) in the United States (US)
T. De, M. Edmondson-Jones, M. Dyer, F. Ejzykowicz +5 more
2022Value in Health0 citations Open access
Semantic Scholar
MSR103 Comparison of Three Indirect Overall Survival (OS) Modeling Approaches in Predicting Long-Term OS Benefit in Randomized Controlled Trials: A Case Study From the Relativity-047 Study
T. Baker, R. Kendall, L. McDonald, A. Moshyk +3 more
2022Value in Health0 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Teitsson×13
Invite
S. Teitsson — researcher profile on SciRah
A. Moshyk×12
Invite
A. Moshyk — researcher profile on SciRah
J. May×10
Invite
J. May — researcher profile on SciRah
F. Ejzykowicz×10
Invite
F. Ejzykowicz — researcher profile on SciRah

×8

Invite

L. Leung — researcher profile on SciRah

Invite

M. Patel — researcher profile on SciRah

Invite

S. Kroep — researcher profile on SciRah

Invite

M. Dyer — researcher profile on SciRah

S. Srinivasan×7

Invite

S. Srinivasan — researcher profile on SciRah

Invite

B. Malcolm — researcher profile on SciRah

Invite

S. Kotapati — researcher profile on SciRah

Invite

A. Moshyk — researcher profile on SciRah